MetaCap

InfuSystems (INFU) vs Neuropace (NPCE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InfuSystems (INFU) has outperformed Neuropace (NPCE) over the past year, gaining 51.7% versus a loss of 44.6%. Over five years, INFU leads with a -15.9% price change compared with -32.8% for NPCE. InfuSystems is the larger company by market cap ($287.5 million vs $273.9 million), about 1.0 times the size, while Neuropace is growing revenue faster (+25.1% vs +6.4%).

InfuSystems converts more of its revenue into profit, with a net margin of 4.6% versus -21.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INFU+51.69%NPCE-44.60%
+67%+7%-53%
Nov 21, 20251 yearNov 20, 2026
INFU-19.70%NPCE-32.91%
+62%-17%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INFU versus NPCE key metrics
MetricINFUNPCE
Share price$14.35$7.95
Market cap$287.48M$273.89M
1-day change+2.06%-2.33%
YTD return+59.98%-48.51%
1-year return+51.69%-44.60%
5-year return-15.93%-32.80%
P/E ratio (TTM)32.61—
Forward P/E25.63—
EPS (TTM)$0.44$-0.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$143.44M$99.99M
Revenue growth (YoY)+6.36%+25.13%
Net income (latest FY)$6.63M$-21.46M
Gross margin55.98%77.23%
Operating margin8.31%-16.34%
Net margin4.62%-21.47%
52-week high$15.47$19.60
52-week low$7.29$5.46
Distance from 52-week high-7.24%-59.44%
Analyst consensusstrong_buybuy
Avg. price target upside+28.92%+53.71%
Average volume136.60K270.76K
Shares outstanding20.03M34.45M
Employees461216
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INFU has outperformed NPCE by 96.3 percentage points over the past year.
  • InfuSystems is more profitable, keeping 4.6 cents of every revenue dollar as net income versus -21.5 cents for Neuropace.
  • Neuropace grew revenue faster in its latest fiscal year (+25.13% vs +6.36%).

About InfuSystems

INFU stock →

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.

Health Care · Medical/Dental Instruments · 461 employees

About Neuropace

NPCE stock →

NeuroPace, Inc. operates as a medical device company in the United States.

Health Care · Medical/Dental Instruments · 216 employees

INFU vs NPCE FAQ

Which is bigger, InfuSystems or Neuropace?

InfuSystems (INFU) is larger, with a market capitalization of $287.48M compared with $273.89M for Neuropace (NPCE).

Which stock has performed better over the past year, INFU or NPCE?

INFU returned +51.69% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.

Are InfuSystems and Neuropace in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons